Fleckenstein-Grün G, Fleckenstein A
Basic Res Cardiol. 1981 Sep-Oct;76(5):550-5. doi: 10.1007/BF01908359.
The great extramural coronary stem arteries (as well as extramural collaterals and anastomoses) deserve particular interest with respect to their peculiar susceptibility to autonomic neurotransmitters and drugs. Obviously these arteries, preferentially affected by atherosclerotic processes, are most responsive to such vasodilators which block vascular tone and contractility by interference with Ca-dependent excitation-contraction coupling. This applies first of all to the new pharmacological family of Ca-antagonists but also to the classical nitrites. As we have emphasized in 1971. Ca-antagonism is a new principle of coronary vascular dilation with profound clinical implications (5). In fact, the Ca-antagonists have become, within a few years, the drugs of choice for the treatment of all spastic forms of angina. By contrast adenosine, dipyridamole, chromonar and theophylline preferably dilate the small intramural resistance vessels, but do not significantly reflex the extramural stem arteries. Therefore, in coronary heart disease, the latter drugs do usually not produce major circulatory improvement.
大的壁外冠状动脉主干(以及壁外侧支循环和吻合支)因其对自主神经递质和药物的特殊易感性而值得特别关注。显然,这些动脉优先受到动脉粥样硬化过程的影响,对那些通过干扰钙依赖性兴奋 - 收缩偶联来阻断血管张力和收缩性的血管扩张剂反应最为敏感。这首先适用于新的钙拮抗剂药理学类别,也适用于经典的亚硝酸盐类。正如我们在1971年所强调的,钙拮抗作用是冠状动脉血管扩张的一个新原理,具有深远的临床意义(5)。事实上,在几年内,钙拮抗剂已成为治疗所有痉挛性心绞痛的首选药物。相比之下,腺苷、双嘧达莫、色满卡林和茶碱主要扩张壁内小阻力血管,但对壁外主干动脉没有明显影响。因此,在冠心病中,后一类药物通常不会带来显著的循环改善。